Introduction
Replication-deficient adenovirus vectors (AdVs) have been used to transfer genes into a variety of cell types and tissues, including the heart, arteries, lung, brain and muscles. 1 However, AdVs exhibit time-limited transgene production dependent on the presence of neutralizing host antibodies 2 and on the activation of ill-defined transcriptional silencing mechanisms. 3 The immediate-early region of mouse and human cytomegalovirus (CMV), present in many AdVs, is one of the most potent enhancer/promoters available and generates high levels of exogenous genes expression in a large number of cell types and tissues. [4] [5] [6] It retains cis regulatory elements recognized by ubiquitous transcription factors including AP-1, 7 CREB, 8 NF-kB 9,10 and retinoic acid nuclear receptors (RARs). 11, 12 Despite these properties, CMV-based expression cassettes show timelimited transcriptional activity which is usually silenced within a few days after their introduction in target cells 3, 10 both in vitro and in vivo. This phenomenon has been recently associated with the production of cytokines, such as interferon-␥ (INF-␥), capable of suppressing transgene expression. 3 Those mechanisms leading to repression of gene transcription are poorly characterized. Recent advances indicate that chromatin remodeling is important for the active transcription of expressed genes. 13 Condensed chromatin, in fact, negatively influences DNA accessibility to transcription factors and histone acetylation is required for DNA opening and active transcription. This process is catalyzed by histone acetyl-transferases (HATs) and by their counterpart histone-deacetylases (HDACs). 14 The balance between the activity of these two families of molecules may determine the hyper-or hypo-acetylation of histones important for the positive and negative transcriptional regulation of cellular genes, 15 respectively. Once in the cell nucleus, the adenovirus genome undertakes a structural organization characterized by the presence of acetylated histone-like proteins resembling that of cellular genes 16, 17 and suggesting the possibility that viral and cellular DNA are regulated by similar mechanisms. Early studies, in fact, described a general increase of histone acetylation, obtained by using HDAC inhibitors, which stirred the production of transgenes delivered by AdVs. 18 In the present study we investigated the effects of the transcriptionally active drugs retinoic acid (RA) and trichostatin A (TSA), a potent inhibitor of HDACs, on AdV activity in a series of in vitro and in vivo experiments. Remarkably, the coincident or timely delayed administration of combined RA and TSA, significantly enhanced transgene production and prolonged its lifespan in infected cells and tissues. These results indicate that associated pharmacological treatments with tran-scriptionally active drugs may improve the efficency of AdVs suitable for gene therapy applications.
Results

RA and TSA effects on AdV-mediated transgene expression in vitro
The primary CMV promoter sequence shows the presence of several functional RA responsive elements (RARE). 12 Typically, RA modulates gene expression by the activation of RARs that in turn associate with a number of co-activators some of which are members of the HAT family. In this context, the HDAC inhibitor TSA is known to enhance the transcriptional effect of RA. 18 Therefore we evaluated if RA and TSA alone or in combination modulate AdV-mediated transgene expression. AdCMV.LacZ-infected cells exposed to RA concentrations ranging from 1 to 1000 nm exhibited an enhancement in transgene production with a peak three fold increase above control at 10 nm (Figure 1a) . Similarly, Gene Therapy exposure of infected cells to a range of TSA concentrations from 0.5 to 100 nm revealed a two-to 2.5-fold increase in transgene level between 16-32 nm (Figure 1b) . Remarkably, the enhancement of transgene expression upon exposure to both RA and TSA was more marked than that induced by either drug alone and greater than the additive effect of RA and TSA. Indeed, 10 nm RA with 32 nm TSA increased transgene production sevento eight-fold above control (Figure 1c) . These results indicate that the activation of an RA-dependent pathway and HDAC inhibition improve AdV performance.
In additional experiments it was examined whether the viral dose needed to achieve a given level of transgene production could be significantly reduced by treating cells with RA/TSA. It was found that in the presence of RA/TSA the dose-response curves to AdCMV.LacZ ( Figure 2a ) and AdCMV.VEGF 165 ( Figure 2b ) were shifted to the left. These results suggest that transcriptionally active drugs may reduce the virus dose requirement needed for therapeutic effects.
RXR/RAR activation modulates AdV-mediated transgene expression
The presence of multiple functional RARE elements in the CMV promoter sequence 12 prompted us to investigate whether the RA and TSA effects on transgene expression involve RARs activation. In transient transfection experiments endothelial cells were infected with 50 p.f.u. per cell of AdCMV.VEGF 165 24 h after transfection with RAR and RXR expression vectors. Figure 3 shows that BAEC overexpressing RA receptors produced more VEGF than controls and, in the presence of RA/TSA, the level of transgene production increased 10-to 15-fold above controls treated only with RA/TSA. This experiment suggests that RA and TSA could modulate AdV transgene production with a mechanism similar to that regulating endogenous genes.
RA and TSA effects on transgene expression in vivo
In vivo experiments were performed to determine whether RA/TSA modulate AdV-mediated transgene expression in rat skeletal muscle. In these studies AdCMV.LacZ (10 7 or 10 8 p.f.u.) was injected directly in rat quadriceps muscle either in conjunction or without RA and/or TSA. Figure 4 shows that coinjection of AdCMV.LacZ with RA, TSA or both RA/TSA induced a marked increase in transgene production above control. Remarkably, in the presence of RA/TSA, peak transgene expression in response to 10 7 p.f.u. AdCMV.LacZ was 40% higher than that induced by 10 8 p.f.u. injected with solvent alone. Further, the effect of RA/TSA to enhance transgene expression was more marked than that of either RA or TSA. These data indicate that co-injection of AdV with RA, TSA or both RA/TSA in vivo enhances transgene expression.
Delayed RA and TSA treatment reactivates AdV mediated transgene expression in vitro and in vivo Viral and cellular gene expression may be silenced by still poorly understood mechanisms that involve gene methylation, 19 histone de-acetylation 15 and chromatin tightening. 20 Specifically, CMV promoter as well as simian virus 40 (SV40) or rous sarcoma (RSV) promoters may be silenced by the action of cytokines produced by infected cells. 3 However, recent evidence indicates that HDAC inhibitors may strongly activate a chromatin integrated viral promoter 21 and it is possible that this mechanism may be exploited to reactivate a silenced viral promoter. This issue was addressed in the experiments described below. BAEC were infected with AdCMV.LacZ (50 p.f.u. per cell) and exposed to RA (10 nm) and TSA (32 nm) at different times after infection, 24 h before harvesting. Figure 5a shows that post-infection treatment with RA/TSA increased transgene production about 10-fold at day 2 while at time-points in which ␤-galactosidase activity was barely detectable in untreated controls, ie days 6, 8, 10 and 12 after infection, it consistently reactivated transgene production.
A similar experiment was repeated in vivo; male Wistar rats were co-injected with RA/TSA and AdCMV.LacZ while in other rats RA/TSA were injected into the skeletal muscle at different times after infection with the viral vector but at the same site where the AdV had been previously injected. Figure 5b shows that when RA/TSA were co-injected with the virus, transgene production was enhanced about four-to five-fold above control levels reaching a peak at day 4 compared with day 2 in controls. Another animal group received RA/TSA both at time 0 and at day 5, and a third group received RA/TSA at time 0, at day 5 and at day 14. In these groups the decline in transgene production was delayed and ␤-galactosidase activity was detectable up to 24 days after infection. In contrast, in control conditions, enzyme activity became negative between days 8 and 10 after infection (open squares). It is noteworthy that the time of peak transgene expression, when RA/TSA were coinjected with the viral vector, was day 6 in the experiments described in Figure 4 and day 4 in the experiments depicted in Figure 5b . The mechanism for this difference is currently unclear, however, it is possible that it may be related to batch-to-batch variability in contaminants of the viral preparation. 22 Nevertheless, the major point in our experiments is that RA/TSA enhance and delay transgene expression versus control regardless of the precise timing of peak ␤-gal activity. Taken together, the results suggest that the progressive reduction of transgene expression that follows AdV-mediated gene transfer into mammalian cells both in vitro and in vivo, is dependent on transcriptional silencing processes sensitive to HAT and HDAC activity.
Discussion
Recombinant AdVs are increasingly used in gene transfer studies in tissue culture conditions, in animal models and in humans. However, their time-limited capacity of transgene expression and antigenic features limit their full scale utilization. Strategies aimed at enhancing and sustaining AdV-mediated transgene production may, there- fore, be relevant to the clinical application of these viral vectors. The present report describes that the combination of RA and the antibiotic TSA, a potent HDAC inhibitor, enhances and prolongs AdV-mediated transgene expression in cultured cells and living tissues. In vitro this effect was markedly enhanced in cells expressing RXR/RAR complexes ( Figure 2 ). The mechanism of RA action implies that ligand-activated RARs associate with co-activators, members of the HAT family, 23 and bind to DNA, promoting chromatin rearrangement and gene transcription activation. The recombinant AdVs used in the present study carry a CMV promoter driven expression cassette. CMV promoter retains repeated RARE and it is responsive to an in vitro RA treatment. 12 Based on our observations, the effect of RA may be the consenquence of a direct RXR/RAR activation and stimulation of CMV transcription. Further, TSA, increased three-to eight-fold in transgene production both in vitro and in vivo. Therefore we hypothesize that the intracellular balance between HAT and HDAC activity, normally important for cellular gene expression, it is also relevant for AdV function. In fact, it has been observed that, in infected cells, the wild-type adenovirus genome is complexed with the histone-like basic protein VII present in the Ad core. 16, 17 The core is organized in nucleosome-like structures in which the proteic components are acetylated and similar to cellular histones. 16, 17 It is conceivable that AdV-mediated gene expression will be sensitive to the acetylation level of the virus DNA structural proteins. In this regard, previous work demonstrated that HDAC inhibitors alone may modulate in vitro AdV transgene expression. 18 Our experiments, however, demonstrated that the association of RA and TSA strongly cooperated not only enhancing transgene production, but also extending temporally its expression in the target cells or tissues. The mechanism by which gene expression is silenced, presumably by the formation of tight chromatin, is not yet well understood. DNA methylation is one of the mechanism most commonly ascribed to control gene inactivation and re-expression 19 but this process does not
Gene Therapy seem involved in the negative regulation of AdVsmediated transgene expression. 10 Recent observations indicated that hystone de-acetylation contributes to the repression of expressed genes. 15 In this regard, Figure 5 shows that RA/TSA re-activates transgene prodution in vitro and in vivo. These results support the possibility that structural modifications of the viral chromatin occurring in the region of transgene insertion may determine the progressive decline of transgene production that is commonly observed in spite of the persistent presence of the viral genome. 24 Further studies are required to better elucidate this point. Nevertheless, the association of transcriptionally active drugs introduced locally with recombinant AdVs may represent a novel approach to improve the performance of these vectors and decrease the viral load to which the tissues are exposed.
Materials and methods
Adenoviral vectors
AdCMV.LacZ and AdCMV.VEGF 165 have been previously described. 25, 26 Viruses were amplified in 293 cells and titered by plaque forming assay according to standard protocols. Viral stocks were maintained at −80°C for long-term storage before use.
Cell culture and infection
Bovine aortic endothelial cells (BAEC) were freshly obtained from bovine isolated aortas as previously described. 27 Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; HyClone Laboratories, Sigma Chemical Co, St Louis, MO, USA) containing 1 mm glutamine, 100 units/ml penicillin/streptomycin, and 10% fetal bovine serum (FBS; HyClone Laboratories). Typically 10 6 BAEC (passage 5 to 11) were plated in 100-mm plates and 12 h after plating, washed in phosphatebuffered saline (PBS, Life Technologies, Paisley, UK) and infected either with AdCMV.VEGF 165 or with AdCMV.LacZ in the presence of DMEM supplemented with 1% FBS. One hour after infection cells were washed in 1 × PBS and then cultured in DMEM supplemented with 10% FBS.
per cell AdCMV.LacZ for 1 h at the zero time-point (not shown). After infection cells were cultured in complete DMEM (10% FBS
RA and TSA treatments All-trans RA (Sigma Chemical) and TSA (Sigma Chemical) were dissolved in ethanol to a stock concentration of 5 × 10 −3 m or 10 × 10 −6 m and stored at −80°C before use. All experiments were performed under low light conditions to minimize RA photo-isomerization. For in vitro experiments, RA and TSA were diluted with DMEM to the final concentration. Typically, 10 6 BAEC were infected with different doses of AdCMV.VEGF 165 , or AdCMV.LacZ in each experiment. Twenty-four hours after infection cells were exposed to RA and/or TSA at the experimental concentration. Control cells were exposed to equal quantities of solvent. For the in vivo experiments, all solutions were freshly prepared immedi-ately before use and directly injected in the skeletal muscle together with the different AdVs or at defined times after viral infection.
ELISA
Vascular endothelial growth factor (VEGF) was measured using a commercial ELISA that recognizes human VEGF (R&D System, Abingdon, UK). This assay was performed according to the manufacturer's protocol. For the quantitative determination of VEGF in the conditioned medium (CM) of infected cells, about 10 6 BAEC were plated in 100 mm dishes and infected with different doses of AdCMV.VEGF 165 . After 24 h the bathing medium was substituted with fresh DMEM with 1% FCS, supplemented with RA and/or TSA and cultured for 2 additional days. CMs were collected and stored at −80°C until assayed. Protein concentration in each sample was determined by Bradford assay (BioRad Lab, Hercules, CA, USA); 300 g of protein of each sample were used for ELISA determination of VEGF concentration.
Transient transfections
Either pCMVRAR␣, pCMVRAR␤, pCMVRAR␥ and pCMVRXR␤ in different combinations or pCMV control vector (4 g) and pCMV␤-gal expression vector (1 g) were transfected into BAEC by lipofectamine-plus reagent (GIBCO BRL, Life Technologies Ltd, Paisley, UK) according to the manufacturer's instructions. pCMV␤-gal was added to all transfections for sample normalization. BAEC (10 6 cells in each point) were first transfected for 6 h and recovered in fresh medium for an additional 24 h. Subsequently cells were infected with AdVs (50 p.f.u. per cells) as described above and the exposure to the viral vectors was interrupted by replacing the bathing medium with complete DMEM supplemented with 10 nm RA and 32 nm TSA. Cells were cultured for additional 72 h before CMs collection. ␤-Galactosidase activity was measured by a chemiluminescent reporter assay (Promega, Madison, WI, USA), according to the manufacturer's instructions. VEGF quantitation was performed by ELISA as described above.
In vivo infection and determination of ␤-galactosidase activity Quadriceps muscles of male Wistar rats were injected with a total volume of 1 ml of phosphate buffered saline (PBS) containing 10 7 or 10 8 p.f.u. of AdCMV-LacZ alone or in combination with RA (100 nm) and TSA (32 nm) after standard ketamine/xylazine anesthesia. Dead animals were perfused with 250 ml of saline solution and 120 ml PBS through the abdominal aorta, before muscle excision. Each muscle was positioned and pinned on a wooden board. Each specimen was fine minced with scissors and stored at −70°C. Before ␤-gal assay tissue samples were weighed and then lysed in 1.5 ml lysis buffer (100 mm potassium phosphate, 0.2% Triton X-100, 0.5 mm dithiothreitol, 0.2 mm phenylmethanesulfonylfluoride, 0.5 mg/ml leupeptin; pH 7.8) for each gram of tissue. After 1 h of incubation at room temperature samples were homogenized with a tissuemizer (Dispergerate; PBI International, Milan, Italy). Homogenates were centrifuged at 3000 r.p.m. for 20 min at 4°C. Supernatants were transferred to 1.5 ml Eppendorf tubes, and centrifuged at 14 000 g for an additional 20 min. Before assay, clarified samples were transferred in new Gene Therapy tubes and protein concentration was determined by Bradford protein assay (BioRad); 380 g of total lysate protein was incubated with the appropriate reaction buffer for 1 h according to the manufacturer's protocol (Galacto-Light Plus, Tropix, Temecula, CA, USA). The chemilunescence was evaluated by a Topcount reader (Packard, Meriden, CT, USA) and is expressed as counts per second.
Statistical analysis
Results were analyzed by a one-way ANOVA test, followed by Student's t test for significance between unpaired mean values. Post-hoc tests according to the Student-Newman-Keuls method were used when the ANOVA P value indicated a statistically significant difference among test groups. A P Ͻ 0.05 was considered statistically significant. All data are expressed as mean ± standard deviation (s.d.).
